Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
First investment?! Great job! I'm with you, adding when I can. Wish I had the had the opportunity to load millions of shares in double 0's
Jealous. Good job :)
$106..
Added some yesterday, waiting for funds to clear again! Can't get enough
Love it!
"President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board."
That's awesome lol
Can't wait to gobble up some more here Monday! Thank you VPRO for making me hate weekends lol
I'm with you! I don't think Dr. Royston would waste his time with a share selling scam
Spank the 3's
I love the BOD here. Big things coming!
Low volume because nobody is selling! IMO
Nope :(
Thank you. You're right, Dr. Royston wouldn't be on the board of directors of a worthless penny stock! Not giving up my shares, at least not until we hit dollars
Board of directors is the only reason I'm here lol
This has me a bit worried.. Think this is something we should be concerned about?
Prior to joining Itonis, Inc. in 2011, Mr. Pidliskey was a Project Executive for IBM Corporation, retiring after a 32 year career. During his tenure with IBM, he was responsible for worldwide sales and services support with contract revenues exceeding $1B annually. He has extensive experience in leading large complex teams responsible for business operations, strategic planning, change management, business process reengineering, and technical sales support. As an Innovative leader, Mr. Pidliskey is known for building strong teams, integrating strategic business partnerships, and delivering high levels of client satisfaction to customer sets ranging from small and medium size businesses to Fortune 500 companies.
Not on the sidelines, but I really want to load up some more here!
When are financials due by?
I'll be bidding tomorrow, but I'm more like a shrimp.. For now :p
The effort to recruit Dr. Royston was spearheaded by Dr. Kenneth A. Sorensen, a member of Viropro's Board of Directors, who also directed the process leading to the proposed acquisition of NovaRx. "Dr. Royston's background is ideal both for Viropro's long term strategy of building a diversified portfolio of high value assets and the immediate task of completing the clinical development of the NovaRx cancer immunotherapy portfolio," said Dr. Sorensen.
Dr. Royston has been involved in the biotechnology industry in San Diego from its inception in 1978 with the founding of Hybritech, Inc. (later acquired by Eli Lilly) and with the founding of Idec Pharmaceuticals in 1986 (which later merged with Biogen). In 1990, Dr. Royston launched Forward Ventures and has been instrumental in the formation, financing, and development of numerous successful public biotechnology companies, including: Applied Molecular Evolution (acquired by Eli Lilly); Combichem (acquired by DuPont); Corixa (acquired by GlaxoSmithKline); Genesys Therapeutics (merged with Somatix and acquired by Cell Genesys); LigoCyte (acquired by Takeda); Morphotek (acquired by Eisai); TargeGen (acquired by Sanofi-Aventis); and Triangle Pharmaceuticals (acquired by Gilead). Dr. Royston currently serves on the Board of Directors of BioCept, Syndax Pharmaceuticals, HemaQuest Pharmaceuticals, and Tangen Pharmaceuticals Dr. Royston was previously the Founding President and CEO of the Sidney Kimmel Cancer Center (1990-2000) and on the faculty of the medical school and cancer center of the University of California, San Diego (1977-1990). He received his B.A. and M.D degrees from the Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. In 1997, President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board.
SAN JOSE, Calif., Dec. 8, 2015 /PRNewswire/ -- Viropro, Inc. (OTCBB: VPRO), which has previously announced it will be changing its name to Axxiom, today announced that Ivor Royston, M.D. has agreed to join its Board of Directors effective immediately.
Dr. Royston is Founding Managing Member of Forward Ventures and a recognized leader in cancer research. He is widely recognized as a founding father of San Diego's biotech industry. In 1978, he co-founded Hybritech, Inc., San Diego's first biotechnology company, which was subsequently acquired by Eli Lilly & Co. In 1986, Dr. Royston co-founded IDEC Corporation, discoverer of Rituxan®, the first FDA-approved monoclonal antibody to treat B-cell lymphoma, prior to its merger with Biogen.
"We are delighted to have an executive and entrepreneur of Dr. Royston's stature join our Board," said Bruce Cohen, Chairman. "His decades of industry leadership and keen understanding of breakthroughs in cancer therapy will be truly transformative for Viropro as we continue our efforts to build a world-class company."
Because Dr. Royston is a renowned expert in Immuno-Oncology therapies, Viropro believes his value in helping exploit this product category could be significant, especially in light of Viropro's previously announced intention to acquire NovaRx. In addition Dr. Royston will support Viropro's ongoing pursuit of strategic partnerships with pharmaceutical companies and the acquisition of underappreciated assets. He will also play a pivotal role in recruiting senior executives for Viropro. Viropro's Board of Directors was unanimous in its approval of this nomination.
Dr. Royston has been involved in the biotechnology industry in San Diego from its inception in 1978 with the founding of Hybritech, Inc. (later acquired by Eli Lilly) and with the founding of Idec Pharmaceuticals in 1986 (which later merged with Biogen). In 1990, Dr. Royston launched Forward Ventures and has been instrumental in the formation, financing, and development of numerous successful public biotechnology companies, including: Applied Molecular Evolution (acquired by Eli Lilly); Combichem (acquired by DuPont); Corixa (acquired by GlaxoSmithKline); Genesys Therapeutics (merged with Somatix and acquired by Cell Genesys); LigoCyte (acquired by Takeda); Morphotek (acquired by Eisai); TargeGen (acquired by Sanofi-Aventis); and Triangle Pharmaceuticals (acquired by Gilead). Dr. Royston currently serves on the Board of Directors of BioCept, Syndax Pharmaceuticals, HemaQuest Pharmaceuticals, and Tangen Pharmaceuticals Dr. Royston was previously the Founding President and CEO of the Sidney Kimmel Cancer Center (1990-2000) and on the faculty of the medical school and cancer center of the University of California, San Diego (1977-1990). He received his B.A. and M.D degrees from the Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. In 1997, President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board.
http://www.forwardventures.com/ivor_royston.html
Thanks for all the info!
Time travel would come in handy right about now huh? Lol
Same here! Break the resistance at .0215 and run it to a dime!
2mil on the bid at 02
I'm with you. Skeptical that this will move past .0003 lol
ENIP
.0003s falling Monday!
Yes! C'mon newbies, buy my shares at .0001! Let me out of this turd
Hoping this doesn't take off this week! My funds take 3 days before available to trade.
Same here! Nice pull back today, getting ready to hit new highs
ENIP
10 Reasons to Buy ENIP...
1. Holder of four proprietary patents that pertain to smart meter technology.
2. A growing business… $752,000 in revenue last quarter for an estimated rolling 12 months revenue of $3,008,000.
3. 695M shares outstanding.
4. Have been successful in their court fights against larger companies infringing on their patent(s).
5. Some of these court cases have resulted in monetary settlements; others in licensing agreements or both.
6. The current claim is against a company that per its own website states, “more than 200 million metering modules deployed over the course of the last 10 years alone”
7. ENIP has a track record of success in these court fights. A licensing agreement with a company with over 200 million metering modules? The sky’s the limit.
8. The stock closed at .001 just seven weeks ago when it was carrying a lot of debt.
9. As has been the case with their other legal successes, on November 3rd, the company won a declaratory judgment removing all financial obligations under four promissory notes totaling $1.9 Million plus accrued interest rendering the company close to debt free and a buyout candidate.
10. Just with the current licensing agreements at 1X sales and 695M shares, the company valuation would/should be .0043
.001! $$$$
$ENIP
10 Reasons to Buy ENIP...
1. Holder of four proprietary patents that pertain to smart meter technology.
2. A growing business… $752,000 in revenue last quarter for an estimated rolling 12 months revenue of $3,008,000.
3. 695M shares outstanding.
4. Have been successful in their court fights against larger companies infringing on their patent(s).
5. Some of these court cases have resulted in monetary settlements; others in licensing agreements or both.
6. The current claim is against a company that per its own website states, “more than 200 million metering modules deployed over the course of the last 10 years alone”
7. ENIP has a track record of success in these court fights. A licensing agreement with a company with over 200 million metering modules? The sky’s the limit.
8. The stock closed at .001 just seven weeks ago when it was carrying a lot of debt.
9. As has been the case with their other legal successes, on November 3rd, the company won a declaratory judgment removing all financial obligations under four promissory notes totaling $1.9 Million plus accrued interest rendering the company close to debt free and a buyout candidate.
10. Just with the current licensing agreements at 1X sales and 695M shares, the company valuation would/should be .0043
ENIP
10 Reasons to Buy ENIP...
1. Holder of four proprietary patents that pertain to smart meter technology.
2. A growing business… $752,000 in revenue last quarter for an estimated rolling 12 months revenue of $3,008,000.
3. 695M shares outstanding.
4. Have been successful in their court fights against larger companies infringing on their patent(s).
5. Some of these court cases have resulted in monetary settlements; others in licensing agreements or both.
6. The current claim is against a company that per its own website states, “more than 200 million metering modules deployed over the course of the last 10 years alone”
7. ENIP has a track record of success in these court fights. A licensing agreement with a company with over 200 million metering modules? The sky’s the limit.
8. The stock closed at .001 just seven weeks ago when it was carrying a lot of debt.
9. As has been the case with their other legal successes, on November 3rd, the company won a declaratory judgment removing all financial obligations under four promissory notes totaling $1.9 Million plus accrued interest rendering the company close to debt free and a buyout candidate.
10. Just with the current licensing agreements at 1X sales and 695M shares, the company valuation would/should be .0043
10 Reasons to Buy ENIP...
1. Holder of four proprietary patents that pertain to smart meter technology.
2. A growing business… $752,000 in revenue last quarter for an estimated rolling 12 months revenue of $3,008,000.
3. 695M shares outstanding.
4. Have been successful in their court fights against larger companies infringing on their patent(s).
5. Some of these court cases have resulted in monetary settlements; others in licensing agreements or both.
6. The current claim is against a company that per its own website states, “more than 200 million metering modules deployed over the course of the last 10 years alone”
7. ENIP has a track record of success in these court fights. A licensing agreement with a company with over 200 million metering modules? The sky’s the limit.
8. The stock closed at .001 just seven weeks ago when it was carrying a lot of debt.
9. As has been the case with their other legal successes, on November 3rd, the company won a declaratory judgment removing all financial obligations under four promissory notes totaling $1.9 Million plus accrued interest rendering the company close to debt free and a buyout candidate.
10. Just with the current licensing agreements at 1X sales and 695M shares, the company valuation would/should be .0043
ENIP
10 Reasons to Buy ENIP...
1. Holder of four proprietary patents that pertain to smart meter technology.
2. A growing business… $752,000 in revenue last quarter for an estimated rolling 12 months revenue of $3,008,000.
3. 695M shares outstanding.
4. Have been successful in their court fights against larger companies infringing on their patent(s).
5. Some of these court cases have resulted in monetary settlements; others in licensing agreements or both.
6. The current claim is against a company that per its own website states, “more than 200 million metering modules deployed over the course of the last 10 years alone”
7. ENIP has a track record of success in these court fights. A licensing agreement with a company with over 200 million metering modules? The sky’s the limit.
8. The stock closed at .001 just seven weeks ago when it was carrying a lot of debt.
9. As has been the case with their other legal successes, on November 3rd, the company won a declaratory judgment removing all financial obligations under four promissory notes totaling $1.9 Million plus accrued interest rendering the company close to debt free and a buyout candidate.
10. Just with the current licensing agreements at 1X sales and 695M shares, the company valuation would/should be .0043
$ENIP set up to explode this week!
What makes you think that?
Pump and dump! Tomorrow comes the massive dump.
DUMP coming tomorrow